News | Antiplatelet and Anticoagulation Therapies | November 14, 2016

Study Finds Blood Clot Prevention Medications Equally Safe and Effective for PCI Patients

Results find rates of major bleeding and other adverse events statistically similar with bivalirudin versus heparin with short-term tirofiban infusion

bivalirudin, heparin, blood clot prevention medication, PCI, percutaneous coronary intervention, Intermountain study, AHA Scientific Sessions

November 14, 2016 — Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention (PCI), according to a new study.

The scientific community has proposed both medications as potentially superior to longer-term anticoagulation treatments for patients undergoing the non-surgical procedure to open blood vessels narrowed by plaque buildup.

The new study by researchers from the Intermountain Medical Center Heart Institute in Salt Lake City sought to discover which of the two short-term treatment methods —using the drug heparin combined with a short-term (less than six hours) infusion of tirofiban, or short-term periprocedural bivalirudin, another medication that helps prevent blood clots during the procedure — was more effective.

Through this observational study of patients undergoing successful elective PCI, the Intermountain researchers found the risk after 30 days of major bleeding, and one-year risk of death, heart attack and urgent repeat PCI, was low and not significantly different between the two treatment methods.

Results of the study were presented during the American Heart Association Scientific Sessions, Nov. 12-16 in New Orleans.

“Bivalirudin has been considered the gold standard for reducing bleeding during percutaneous coronary intervention, but our study shows heparin plus short-term tirofiban is just as good and possibly better,” said Intermountain Medical Center Heart Institute cardiologist J. Brent Muhlestein, M.D., the lead author on the study. “The results certainly justify a randomized clinical trial to explore identified trends.”

Researchers studied results from patients who underwent PCI between January 2013 and December 2015. Of the 857 patients enrolled in the study, 402 received heparin plus short-term tirofiban treatment and 455 received bivalirudin. The patients were between the ages of 51 and 78.

There was a slight reduction in major bleeding and death with the use of heparin plus short-term tirofiban over bivalirudin alone, but due to the overall low incidence of adverse events, the difference did not reach statistical significance.

The 30-day incidence of TIMI (Thrombolysis in Myocardial Infarction) major bleeding score was 1.2 percent for patients treated with heparin and tirofiban and 3.1 percent for bivalirudin patients.

In addition to Muhlestein, other members of the Intermountain Medical Center Heart Institute research team include: Heidi T. May, Ph.D.; Tami L. Bair; Viet Le, PA-C; Jeffrey L. Anderson, M.D.; Brian Whisenant, M.D.; Kirk U. Knowlton, M.D.; and Donald L. Lappé, M.D.

For more information: www.scientificsessions.org

Related Content

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Overlay Init